Capsugel Expands Global Manufacturing for Finished Dosage Forms
Complete the form below to unlock access to ALL audio articles.
Capsugel’s Dosage Form Solutions (DFS) business unit has unveiled extensive upgrades and expansions to three of its manufacturing facilities in the United States and Europe, deepening the company’s finished dosage form capabilities as part of its LIPIDEX® technology platform.
The multi-million dollar investments broaden the company’s global capabilities to handle hormonal as well as high potent compounds for soft gelatin and liquid-fill hard capsules (LFHC), responding to a growing demand from its pharmaceutical and health and nutrition customers.
“Investments at our soft gelatin and LFHC facilities reinforce Capsugel’s leadership in liquid-fill technologies and our commitment to offering customers a comprehensive range of services from formulation development to commercial manufacturing. Backed by decades of capsule engineering, specialized formulation know-how and global supply chain expertise, customers can be assured of high quality encapsulated products using SGcaps® and Licaps® technology,” said Anthony Macci, SVP of Global Operations.
Macci continued, “Our continued expansion and integration of our product development and manufacturing capabilities further ensures that customer projects find optimized solutions, fast.”
Investment highlights include:
• Ploermel facility in France: Increased containment capacity to handle hormonal as well as high-potent compounds in softgel manufacturing at this FDA-inspected and MHRA/ANVISA-accredited site. Specific upgrades include a new, high precision dosing system and high-speed capsule printing capability.
• Livingston facility in the UK: Expanded with additional laboratory space, equipment and analytical scientists at this FDA/MHRA-accredited site. The latest generation CFS 1500 capsule filling and sealing machine, which incorporates proprietary Fusion technology, has been installed, and the proprietary lipid expert system has been incorporated into the team’s finished dosage form development process.
• Greenwood facility in the U.S.: Commissioned and validated a new commercial scale liquid-fill encapsulation unit for pharmaceutical applications. The installation of commercial production capability for the new solid lipid pellet (SLP) technology has also been initiated. SLP technology is currently being used on select customer development projects as a unique lipid-based formulation option for bioenhancement and other formulation issues.
